VHH polypeptides that bind to
Polypeptide products, methods, pharmaceutical compositions, and kits are provided for treating a subject exposed to, or at risk for exposure to, C. difficile microbial pathogens and toxin B produced by C. difficile (TcdB) pathogens. The methods, compositions and kits include a single domain, anti-TedB VHH polypeptide (antibody), or toxin B binding portion thereof, that specifically binds to and/or neutralizes TedB and treats or prevents illness and disease associated with C. difficile infection and TedB intoxication. The anti-TcdB VHHs, or toxin B binding portion thereof, may be recombinantly produced.
1. A polypeptide that specifically binds to Clostridium difficile ( C. difficile ) toxin B (TcdB), or a TcdB-binding portion thereof, wherein the polypeptide comprises three complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, and four VHH framework regions (FRs), FR1, FR2, FR3 and FR4, with the general structure FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4,
wherein CDR1 comprises amino acid sequence GSVYTF (SEQ ID NO: 25); CDR2 comprises amino acid sequence SGGTITK (SEQ ID NO: 26); and CDR3 comprises amino acid sequence NAGDTIAQAMGTRRFPFDR (SEQ ID NO: 27);
wherein CDR1 comprises amino acid sequence GTSFPRNY (SEQ ID NO: 28); CDR2 comprises amino acid sequence SHDGNVE (SEQ ID NO: 29); and CDR3 comprises amino acid sequence KLVTLRRDEY (SEQ ID NO: 30);
wherein CDR1 comprises amino acid sequence RFSLINYA (SEQ ID NO: 31); CDR2 comprises amino acid sequence TSGGATY (SEQ ID NO: 32); and CDR3 comprises amino acid sequence AAGPYSRTLVSRWKVGDGMEY (SEQ ID NO: 33);
wherein CDR1 comprises amino acid sequence GFTSNSYY (SEQ ID NO: 34); CDR2 comprises amino acid sequence SSSGGSPN (SEQ ID NO: 35); and CDR3 comprises amino acid sequence AASKFPLTTMASNRYHY (SEQ ID NO: 36);
wherein CDR1 comprises amino acid sequence GRGPGINV (SEQ ID NO: 37); CDR2 comprises amino acid sequence QTGGTTN (SEQ ID NO: 38); and CDR3 comprises amino acid sequence YLKKWRDEY (SEQ ID NO: 39);
wherein CDR1 comprises amino acid sequence GSSFSMNV (SEQ ID NO: 40); CDR2 comprises amino acid sequence RSDGITN (SEQ ID NO: 41); and CDR3 comprises amino acid sequence FHGRARTGNNADLGS (SEQ ID NO: 42);
wherein CDR1 comprises amino acid sequence GRLSERIFMIST (SEQ ID NO: 43); CDR2 comprises amino acid sequence SRLGRAN (SEQ ID NO: 44); and CDR3 comprises amino acid sequence NLKPFVDNYR (SEQ ID NO: 45);
wherein CDR1 comprises amino acid sequence GITFSNVA (SEQ ID NO: 46); CDR2 comprises amino acid sequence STGGSSTS (SEQ ID NO: 47); and CDR3 comprises amino acid sequence VKGPKYSATIRRPE (SEQ ID NO: 48);
wherein CDR1 comprises amino acid sequence GFNFSVQI (SEQ ID NO: 49); CDR2 comprises amino acid sequence STGGASKS (SEQ ID NO: 50); and CDR3 comprises amino acid sequence SKGPRTWINSSPR (SEQ ID NO: 51);
wherein CDR1 comprises amino acid sequence GTAFSLDT (SEQ ID NO: 52); CDR2 comprises amino acid sequence SSSGASN (SEQ ID NO: 53); and CDR3 comprises amino acid sequence YRGRVRGVWPLDSGMMY (SEQ ID NO: 54);
wherein CDR1 comprises amino acid sequence GSILSS (SEQ ID NO: 55); CDR2 comprises amino acid sequence SRTGATD (SEQ ID NO: 56); and CDR3 comprises amino acid sequence NAGLGMGDPRRPGPW (SEQ ID NO: 57); or
wherein CDR1 comprises amino acid sequence ERNPGINA (SEQ ID NO: 58); CDR2 comprises amino acid sequence WQTGGSLS (SEQ ID NO: 59); and CDR3 comprises amino acid sequence YLKKWRDQY (SEQ ID NO: 60).
2. The polypeptide of claim 1 , wherein the polypeptide neutralizes C. difficile toxin B (TcdB) activity.
3. The polypeptide of claim 1 , which is a camelid-derived single domain anti-TcdB VHH antibody.
4. The polypeptide or the TedB-binding portion thereof of claim 1 , wherein the polypeptide or the TedB-binding portion thereof has at least 85% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23; wherein amino acid sequence variation occurs in one or more framework (FR) regions of the polypeptide.
5. The polypeptide of claim 4 , wherein the sequence variation comprises conservative amino acid substitutions in the one or more framework (FR) regions of the polypeptide.
6. A polypeptide that specifically binds to C. difficile toxin B (TcdB), or a TcdB-binding portion thereof, wherein the polypeptide or the TedB-binding portion thereof comprises a sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23.
7. A polypeptide that specifically binds to C. difficile toxin B (TcdB), or a TcdB-binding portion thereof, wherein the polypeptide or the TedB-binding portion thereof consists of a sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23.
8. A dimeric or multimeric polypeptide comprising two or more anti-TcdB VHH polypeptides or TcdB binding regions thereof comprising a sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23, wherein the two or more anti-TcdB VHH polypeptides, or the TedB binding regions thereof, are joined with one or more linker peptides.
9. The dimeric or multimeric polypeptide of claim 8 , wherein the one or more linker peptides is selected from GGGGS (SEQ ID NO: 63); GGGGSGGGGSGGGGS (SEQ ID NO: 64), or a functional portion thereof;
EPKTPKPQGGGGSGGGGSGGGGSQGVQSQVQLVE (SEQ ID NO: 65); EPKTPKPQ (SEQ ID NO: 66); or a combination thereof.
10. The dimeric or multimeric polypeptide of claim 8 , comprising one or more epitope tag sequences specifically bindable by an anti-epitope tag antibody or binding portion thereof.
11. The dimeric or multimeric polypeptide of claim 10 , wherein the one or more epitope tag sequences comprises at least one of DELGPRLMGK (SEQ ID NO: 61) or GAPVPYPDPLEPR (SEQ ID NO: 62).
12. An isolated polynucleotide comprising a nucleic acid sequence encoding an anti-TcdB VHH of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23.
13. An isolated polynucleotide encoding the polypeptide or the TedB-binding portion thereof of claim 1 , wherein the encoded polypeptide or the TcdB-binding portion thereof has at least 85% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23; wherein amino acid sequence variation occurs in one or more framework (FR) regions of the polypeptide.
14. The polypeptide of claim 1 , wherein the four VHH FRs are camelid VHH FRs.
15. The polypeptide of claim 2 , which is a camelid-derived single domain anti-TcdB VHH antibody.
16. The isolated polynucleotide of claim 13 , wherein the encoded polypeptide or the TedB-binding portion thereof has at least 95% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23.
17. The isolated polynucleotide of claim 13 , wherein the sequence variation comprises conservative amino acid substitutions in the one or more framework (FR) regions of the encoded polypeptide.